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Objectives: To estimate the burden of CVD and the impact of LDL-C lowering in 
patients with FH or ASCVD with uncontrolled LDL-C levels in Saudi Arabia (SA) 
and United Arab Emirates (UAE). MethOds: The number of statin-treated national 
patients with FH or ASCVD with uncontrolled LDL-C≥ 100mg/dL (≥ 2.6 mmol/L) in SA 
and UAE was estimated based on country population and disease prevalence. The 
clinical benefits of evolocumab as an add-on therapy to statins were derived from a 
long-term cardiovascular outcomes study (FOURIER) and the Cholesterol Treatment 
Trialists’ Collaboration, a large meta-analysis of statin outcomes trials, modeled 
over a lifetime to determine the impact on CV events, hospitalization costs, and 
quality adjusted life years (QALY). Results: The number of statin-treated national 
patients with FH or ASCVD with uncontrolled LDL-C was estimated at 28,692 FH 
and 293,697 ASCVD in SA; 2,419 FH and 27,606 ASCVD in UAE. Over the lifetime of 
an individual with FH, the additional LDL-C lowering with evolocumab is projected 
to result in a 0.52 (28%) CVD event reduction, a decrease in hospitalization costs 
of $5,225 USD in SA and $5,008 USD in UAE, and an average increase of 3.26 QALY. 
Similarly, over the lifetime of an individual with ASCVD, the additional LDL-C lower-
ing with evolocumab was projected to result in a 0.44 (23%) CVD event reduction, a 
decrease in hospitalization costs of $4,403 USD in SA and $4,219 USD in UAE, and an 
average increase of 1.84 QALY. cOnclusiOns: CVD burden is significant in SA and 
UAE for FH and ASCVD patients. There is a great potential for clinical and economic 
benefits with further LDL-C reduction using evolocumab on top of statin therapy.
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Objectives: To estimate direct and indirect costs associated to adult Portuguese 
patients with heart failure (HF) in 2014. MethOds: A prevalence-based approach 
was adopted to estimate costs associated to HF. Prevalence in 2014 by the New York 
Heart Association (NYHA) Functional Classification was estimated using micro-
data from a previously conducted national community-based epidemiological 
survey. Only patients at NYHA classes II-IV were considered to have costs and it 
was conservatively assumed that patients were either followed in hospital ambu-
latory care or in primary care. Primary care costs were estimated using a data-
base covering a large population, with records of medications, medical visits and 
medical tests or diagnostic procedures for 25,337 patients with a HF diagnosis in 
2014. Hospital resource consumption was estimated using national DRG microdata. 
Resource utilization in hospital ambulatory care and in emergency department 
(ED) episodes was estimated according to experts’ opinion and the national lit-
erature, respectively. Unit costs were based on the official NHS tariffs. The indirect 
costs associated to patients’ absenteeism and early exit from the labour force were 
based on national sources and conservative assumptions. Results: The class II-IV 
prevalence rate in the population aged 25+ was estimated at 3.4%, corresponding 
to 249,592 patients in 2014. HF patients have about 1.1 million medical visits, over 
36,000 hospitalizations and approximately 53,000 ED episodes. In 2014, the overall 
direct and indirect costs were estimated at € 289.4M with an average annual cost 
per patient of € 1,159. Medication, medical visits, exams/diagnostic procedures, 
hospitalization and ED episodes accounted for 29%, 20%, 21%, 26% and 2% of the 
€ 244.9M direct costs, respectively. The indirect costs associated to absenteeism 
and premature exit from the labour market were estimated at € 16.4M and € 28.1M, 
respectively. cOnclusiOns: Heart failure is a costly condition and should receive 
adequate attention from the Portuguese health policy makers.
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Objectives: We conducted this study to estimate economic burden and find 
unmet needs in 4 Asian countries including Korea (KR), Taiwan (TW), Thailand 
(TH), and Malaysia (MY). MethOds: It was a retrospective, cohort, medical chart 
review, and non-interventional study in 4 countries of 6 tertiary hospitals. With 
different Gross Domestic Product (GDP) per capita (KR $27,811, TW $22,639, TH 
$5,921, MY $11,009), it aimed not to compare the results among countries, but to 
estimate and describe it respectively. Patients who met those criteria were included; 
1) over 19 years old, 2) diagnosed with HF (ICD 9 or 10) codes and 3) ≥ 1 hospitaliza-
tion or ≥ 2 outpatient visit. Index period was one year (Jan. 1 to Dec. 31 in 2014). 
We collected variables including demographics, healthcare cost and resumption 
including drugs. Results: A total of 568 patients were included (KR 200, TW 200, 
TH 100, MY 68). We particularly focused on patients with hospitalization experience 
and there were KR 40, TW 187, TH 49, and MY 48 patients, respectively. In Korea, 
hospitalization cost per event was $7,419 and $10,714 in annual cost per patient. In 
extracted. Only incident adult patients were analyzed (not hospitalized with PAH 
in 2011-2012). A medically pre-defined selection algorithm was completed with the 
input of medical experts in order to exclude any patient identified as presenting 
with another pulmonary hypertension group. Patients were followed for a year 
following their index stay. A separate algorithm and a medical review excluded 
hospitalizations not related to PAH, and classified selected admissions as inclusion 
(diagnosis, treatment initiation), monitoring and worsening, based on the delay of 
admission occurrence, length of stay, reason for hospitalization, presence of certain 
comorbidities and death. Hospital costs associated with PAH management were esti-
mated using published official tariffs in France for 2013 and 2014 expressed in 2015 
Euro. Results: A cohort of 384 patients newly diagnosed with PAH was identified. 
Mean age of patients was 59.6 years old (±16.7), 63% were female. The 1,271 hospital 
stays were classified as: 415 inclusion stays (32.7%), 604 PAH monitoring stays (47.5%) 
and 252 PAH worsening stays (19.8%). The annual economic burden of hospitaliza-
tions for PAH was estimated to € 3.6 million with inclusion stays accounting for 28%; 
monitoring stays for 21%; worsening stays for 51%. The median cost per stay was 
estimated to be € 1,535 [336-108,668], varying from € 1,269 [362-6,825] for monitor-
ing stays to € 4,121 [518-108,668] for worsening stays. Four patients (1%) had a lung 
transplantation, which accounted for 10% of total costs (€ 357,277). cOnclusiOns: 
PAH worsening is a major driver of hospital-related costs supporting the relevance 
of clinically validated therapeutic strategies preventing disease progression.
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Objectives: To estimate, the impact of population ageing on the costs and burden 
of Heart Failure (HF) in Portugal over a twenty-year horizon, between 2014 and 
2034. MethOds: HF costs were estimated using a prevalence-based approach. 
Costs and disability were assumed zero for patients in class I of the New York Heart 
Association (NYHA) Functional Classification. The prevalence rate was estimated 
using microdata from a previous epidemiological survey. Average direct costs per 
patient were estimated using: 1) a primary care national database with records of 
25,337 patients registered with HF; 2) National DRG microdata; 3) expert panel; 4) 
national literature, reports and legislation. Indirect costs associated to patients’ 
absenteeism and early exit from the labour force were considered. The burden was 
measured in Disability Adjusted Life Years (DALY) resulting from the sum of Years 
Lost due to Disability (YLD) and Years of Life Lost (YLL) due to premature death. For 
YLL, mortality rates reported in the European Detailed Mortality Database were 
considered. For YLD, disease duration and the overall incidence were estimated 
using the software DisMod II. Disability weights were retrieved from published 
literature. Population ageing was carried out by a shift-share analysis using the 
official demographic projections. Results: Considering only population ageing 
on a 20-year horizon, HF prevalence (class II-IV) is expected to increase by 25%, 
reaching over 312,000 patients in 2034. Total costs in 2014 and 2034 are estimated, 
respectively, at € 289M and € 364M (at today’s prices), with an increase in the costs 
per inhabitant of 34%. In 2034, total DALY are expected to be 25% higher than in 
2014, from 21,162 to 26,521. The contribution of YLL will increase from 54% to 
61%. cOnclusiOns: Population ageing will substantially increase the burden 
of HF in Portugal. Health policy makers should consider new strategies to deal 
with this problem.
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Objectives: In the absence of local real life mortality & morbidity and costs data 
associated with CHF in the Czech Republic, we aimed to describe CHF socio-eco-
nomic disease burden (DB) from health care system perspective. This is necessary to 
be clarified in order to better understand added value of novel therapies. MethOds: 
We mined data from existing Acute Heart Failure Database (AHEAD). Subgroup of 
1274 patients hospitalized in 2 centers in Moravia for acute heart failure (AHF) and 
afterwards developing CHF that are included in the AHEAD (local registry including 
patients after AHF hospitalization = index hospitalization), were followed up for 2 
years and frequency of hospitalization and their mortality rate were assessed. Six 
endpoints were determined – AHF re-hospitalization, acute coronary syndrome 
hospitalization, cardiovascular (CV) hospitalization, non-CV hospitalization, hos-
pitalization for any cause and overall mortality. Patients were classified into 4 
groups based on outcome they reached – no death and no hospitalization; death 
without hospitalization; hospitalization but no death; hospitalization and death. 
Each hospitalization event was assigned with particular costs based on DRG tariff, 
just in-patient costs were descried. Results: Czech patients were generally older 
than patients in RCTs (median age 75.9 years). After 24 months of follow-up, 36 % of 
patients died and 68.2 % of patients had at least one hospitalization/ died. Average 
number of hospitalizations was 1.2 (SD 1.6). The average annual CHF in-patient 
costs are 2.8k USD (77% of costs attributed to CV hospitalization). Based on 1.6% 
CHF prevalence, there is 5.3% of all direct health care spending in the Czech repre-
sented by hospitalization of CHF patients. cOnclusiOns: Patients in real life are in 
significantly higher risk of hospitalization and all-cause mortality (by approx. 80 %), 
compared to RCT population. Overall HF DB in the Czech is notable and compared 
to published evidence it is greatly underestimated.
